FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2992550365> ?p ?o ?g. }

• W2992550365 abstract "To assess the effectiveness, and cost effectiveness of EECP in patients with severe anginal symptoms, secondary to chronic coronary disease, who are unresponsive to exhaustive pharmacotherapy and not candidates for surgical/percutaneous revascularization procedures (e.g., angioplasty, coronary bypass surgery). To assess the effectiveness, and cost effectiveness of EECP in patients with heart failure.ANGINA: Angina is a clinical syndrome characterized by discomfort in the chest, jaw, shoulder, back or arm. Angina usually occurs in patients with coronary artery disease (CAD) involving ≥1 large epicardial artery. However it can also occur in people with valvular heart disease, hypertrophic cardiomyopathy, and uncontrolled hypertension. CONVENTIONAL APPROACHES TO RESTORING THE BALANCE BETWEEN OXYGEN SUPPLY AND DEMAND FOCUS ON THE DISRUPTION OF THE UNDERLYING DISEASE THROUGH: drug therapy (β blockers, calcium channel blockers, nitrates, antiplatelet agents, ACE inhibitors, statins); life-style modifications (smoking cessation, weight loss); or revascularization techniques such as coronary artery bypass graft surgery (CABG) or percutaneous coronary interventions (PCI). (1) Limitations of each of these approaches include: adverse drug effects, procedure-related mortality and morbidity, restenosis after PCI, and time dependent graft attrition after CABG. Furthermore, an increasing number of patients are not appropriate candidates for standard revascularization options, due to co-morbid conditions (HF, peripheral vascular disease), poor distal coronary artery targets, and patient preference. The morbidity and mortality associated with repeat surgical revascularization procedures are significantly higher, and often excludes these patients from consideration for further revascularizations. (2) Patients with CAD who have chronic ischemic symptoms that are unresponsive to both conventional medical therapy and revascularization techniques have refractory angina pectoris. It has been estimated that greater than 100,000 patients each year in the US may be diagnosed as having this condition. (3) Patients with refractory angina have marked limitation of ordinary physical activity or are unable to perform any ordinary physical activity without discomfort (CCS functional class III/IV). Also, there must be some objective evidence of ischemia as demonstrated by exercise treadmill testing, stress imaging studies or coronary physiologic studies. (1) Dejongste et al. (4)estimated that the prevalence of chronic refractory angina is about 100,000 patients in the United States. This would correspond to approximately 3,800 (100,000 x 3.8% [Ontario is approximately 3.8% of the population of the United States]) patients in Ontario having chronic refractory angina.Heart failure results from any structural or functional cardiac disorder that impairs the ability of the heart to act as a pump. A recent study (5) revealed 28,702 patients were hospitalized for first-time HF in Ontario between April 1994 and March 1997. Women comprised 51% of the cohort. Eighty-five percent were aged 65 years or older, and 58% were aged 75 years or older. Patients with chronic HF experience shortness of breath, a limited capacity for exercise, high rates of hospitalization and rehospitalization, and die prematurely. (6) The New York Heart Association (NYHA) has provided a commonly used functional classification for the severity of HF (7): CLASS I: No limitation of physical activity. No symptoms with ordinary exertion.CLASS II: Slight limitations of physical activity. Ordinary activity causes symptoms.CLASS III: Marked limitation of physical activity. Less than ordinary activity causes symptoms. Asymptomatic at rest.CLASS IV: Inability to carry out any physical activity without discomfort. Symptoms at rest.The National Heart, Lung, and Blood Institute (7) estimates that 35% of patients with HF are in functional NYHA class I; 35% are in class II; 25%, class III; and 5%, class IV. Surveys (8) suggest that from 5% to 15% of patients with HF have persistent severe symptoms, and that the remainder of patients with HF is evenly divided between those with mild and moderately severe symptoms. To date, the diagnosis and management of chronic HF has concentrated on patients with the clinical syndrome of HF accompanied by severe left ventricular systolic dysfunction. Major changes in treatment have resulted from a better understanding of the pathophysiology of HF and the results of large clinical trials. Treatment for chronic HF includes lifestyle management, drugs, cardiac surgery, or implantable pacemakers and defibrillators. Despite pharmacologic advances, which include diuretics, angiotensin-converting enzyme inhibitors, beta-blockers, spironolactone, and digoxin, many patients remain symptomatic on maximally tolerated doses. (6) THE TECHNOLOGY: Patients are typically treated by a trained technician in a medically supervised environment for 1 hour daily for a total of 35 hours over 7 weeks. The procedure involves sequential inflation and deflation of compressible cuffs wrapped around the patient's calves, lower thighs and upper thighs. In addition to 3 sets of cuffs, the patient has finger plethysmogram and electrocardiogram (ECG) attachments that are connected to a control and display console. External counterpulsation was used in the United States to treat cardiogenic shock after acute myocardial infarction. (9;10) More recently, an enhanced version namely enhanced external counterpulsation (EECP) was introduced as a noninvasive procedure for outpatient treatment of patients with severe, uncontrollable cardiac ischemia. EECP is said to increase coronary perfusion pressure and reduce the myocardial oxygen demand. Currently, EECP is not applicable for all patients with refractory angina pectoris. For example, many patients are considered ineligible for therapy due to co-morbidities, including those with severe pulmonary vascular disease, deep vein thrombosis, phlebitis and irregular heart rhythms, and heart failure. (1) Very recently, investigation began into EECP as an adjunctive treatment for patients with HF. Anecdotal reports suggested that EECP may benefit patients with coronary disease and left ventricular dysfunction. The safety and effectiveness of EECP in patients with symptomatic heart failure and coronary disease and its role in patients with nonischemic heart failure secondary to LV dysfunction is unclear. Furthermore, the safety and effectiveness of EECP in the different stages of HF and whether it is only for patients who are refractive to pharmacotherapy is unknown. 2003 HEALTH TECHNOLOGY ASSESSMENT BY THE MEDICAL ADVISORY SECRETARIAT: The Medical Advisory Secretariat health technology assessment (originally published in February 2003) reported on the effectiveness of EECP for patients with angina and HF. The report concluded that there was insufficient evidence to support the use of EECP in patients with refractory stable CCS III/IV angina as well as insufficient evidence to support the use of EECP in patients with HF.The aim of this literature review was to assess the effectiveness, safety, and cost effectiveness of EECP for the treatment of refractory stable CCS III/IV angina or HF. The standard search strategy used by the Medical Advisory Secretariat was used. This included a search of all international health technology assessments as well as a search of the medical literature from December 2002 to March 2006. A modification of the GRADE approach (11) was used to make judgments about the quality of evidence and strength of recommendations systematically and explicitly. GRADE provides a framework for structured reflection and can help to ensure that appropriate judgments are made. GRADE takes into account a study's design, quality, consistency, and directness in judging the quality of evidence for each outcome. The balance between benefits and harms, quality of evidence, applicability, and the certainty of the baseline risks are considered in judgments about the strength of recommendations.The Cochrane and INAHTA databases yielded 3 HTAs or systematic reviews on EECP treatment (Blue Cross Blue Shield Technology Evaluation Center [BCBS TEC], ECRI, and the Centers for Medicare and Medicaid Services [CMS]). A search of Medline and Embase December 2005 - March 2006 (after the literature search cutoff from the most recent HTA) was conducted using key words enhanced external counterpulsation, EECP, angina, myocardial ischemia, congestive heart failure. This search produced 1 study which met the inclusion criteria. This level 4a study was inferior in quality to the RCT which formed the basis of the 2003 Medical Advisory Secretariat recommendation. BCBS reviewed the evidence through November 2005 to determine if EECP improves health outcomes for refractory chronic stable angina pectoris or chronic stable HF. (12) BCBS concluded that the available evidence is not sufficient to permit conclusions of the effect of EECP on health outcomes. Both controlled trials had methodologic flaws (MUST EECP and MUST EECP quality of life studies). The case series and observational studies for both indications while suggestive of a treatment benefit from EECP have shortcomings as well. On March 20 2006, CMS posted their proposed coverage decision memorandum for external counterpulsation therapy. (ABSTRACT TRUNCATED)" @default.
• W2992550365 created "2019-12-13" @default.
• W2992550365 creator A5084751005 @default.
• W2992550365 date "2006-01-01" @default.
• W2992550365 modified "2023-09-23" @default.
• W2992550365 title "Enhanced External Counterpulsation (EECP): An Evidence-Based Analysis." @default.
• W2992550365 cites W1247968195 @default.
• W2992550365 cites W1507130713 @default.
• W2992550365 cites W153351502 @default.
• W2992550365 cites W1566929296 @default.
• W2992550365 cites W173970953 @default.
• W2992550365 cites W1967179955 @default.
• W2992550365 cites W1974485212 @default.
• W2992550365 cites W1986462023 @default.
• W2992550365 cites W1986828668 @default.
• W2992550365 cites W1987312016 @default.
• W2992550365 cites W1990835137 @default.
• W2992550365 cites W1996715185 @default.
• W2992550365 cites W1996897614 @default.
• W2992550365 cites W2007638066 @default.
• W2992550365 cites W2009836882 @default.
• W2992550365 cites W2011828927 @default.
• W2992550365 cites W2011965313 @default.
• W2992550365 cites W2012876742 @default.
• W2992550365 cites W2018276873 @default.
• W2992550365 cites W2023567460 @default.
• W2992550365 cites W2023570091 @default.
• W2992550365 cites W2026036627 @default.
• W2992550365 cites W2027012768 @default.
• W2992550365 cites W2028743274 @default.
• W2992550365 cites W2030744712 @default.
• W2992550365 cites W2045661661 @default.
• W2992550365 cites W2046592465 @default.
• W2992550365 cites W2048040081 @default.
• W2992550365 cites W2051221992 @default.
• W2992550365 cites W2051297356 @default.
• W2992550365 cites W2072356290 @default.
• W2992550365 cites W2074661520 @default.
• W2992550365 cites W2089476892 @default.
• W2992550365 cites W2092759149 @default.
• W2992550365 cites W2093126614 @default.
• W2992550365 cites W2100940310 @default.
• W2992550365 cites W2102632762 @default.
• W2992550365 cites W2103150701 @default.
• W2992550365 cites W2106484311 @default.
• W2992550365 cites W2113396358 @default.
• W2992550365 cites W2120813125 @default.
• W2992550365 cites W2122568575 @default.
• W2992550365 cites W2123071799 @default.
• W2992550365 cites W2125730125 @default.
• W2992550365 cites W2128762851 @default.
• W2992550365 cites W2130999104 @default.
• W2992550365 cites W2131386820 @default.
• W2992550365 cites W2135491318 @default.
• W2992550365 cites W2154115881 @default.
• W2992550365 cites W2157580588 @default.
• W2992550365 cites W2163978931 @default.
• W2992550365 cites W2171854046 @default.
• W2992550365 cites W25649769 @default.
• W2992550365 cites W2009924642 @default.
• W2992550365 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3379533" @default.
• W2992550365 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23074496" @default.
• W2992550365 hasPublicationYear "2006" @default.
• W2992550365 type Work @default.
• W2992550365 sameAs 2992550365 @default.
• W2992550365 citedByCount "3" @default.
• W2992550365 countsByYear W29925503652013 @default.
• W2992550365 countsByYear W29925503652014 @default.
• W2992550365 countsByYear W29925503652020 @default.
• W2992550365 crossrefType "journal-article" @default.
• W2992550365 hasAuthorship W2992550365A5084751005 @default.
• W2992550365 hasConcept C164705383 @default.
• W2992550365 hasConcept C71924100 @default.
• W2992550365 hasConceptScore W2992550365C164705383 @default.
• W2992550365 hasConceptScore W2992550365C71924100 @default.
• W2992550365 hasLocation W29925503651 @default.
• W2992550365 hasOpenAccess W2992550365 @default.
• W2992550365 hasPrimaryLocation W29925503651 @default.
• W2992550365 isParatext "false" @default.
• W2992550365 isRetracted "false" @default.
• W2992550365 magId "2992550365" @default.
• W2992550365 workType "article" @default.